Lineage Cell Therapeutics (LCTX) to Release Earnings on Monday

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) is expected to issue its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect the company to announce earnings of ($0.07) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 5, 2026 at 4:30 PM ET.

Lineage Cell Therapeutics Price Performance

Shares of LCTX opened at $1.92 on Monday. The firm has a market capitalization of $442.23 million, a PE ratio of -6.62 and a beta of 1.73. Lineage Cell Therapeutics has a 1-year low of $0.37 and a 1-year high of $2.09. The company’s fifty day moving average price is $1.70 and its 200-day moving average price is $1.63.

Analyst Upgrades and Downgrades

Several analysts have commented on LCTX shares. HC Wainwright restated a “buy” rating and set a $9.00 price objective on shares of Lineage Cell Therapeutics in a research note on Monday, November 24th. D. Boral Capital reissued a “buy” rating and set a $2.00 target price on shares of Lineage Cell Therapeutics in a report on Monday, February 9th. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $4.67.

Institutional Investors Weigh In On Lineage Cell Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in Lineage Cell Therapeutics by 6.2% in the third quarter. Vanguard Group Inc. now owns 9,006,930 shares of the company’s stock valued at $15,222,000 after acquiring an additional 524,057 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Lineage Cell Therapeutics by 3.1% in the third quarter. Millennium Management LLC now owns 2,680,003 shares of the company’s stock valued at $4,529,000 after buying an additional 79,426 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Lineage Cell Therapeutics by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 2,461,193 shares of the company’s stock valued at $4,112,000 after buying an additional 41,427 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Lineage Cell Therapeutics by 26.2% during the fourth quarter. Renaissance Technologies LLC now owns 2,404,800 shares of the company’s stock worth $4,016,000 after buying an additional 499,167 shares during the period. Finally, Dauntless Investment Group LLC grew its holdings in shares of Lineage Cell Therapeutics by 33.8% during the third quarter. Dauntless Investment Group LLC now owns 1,614,100 shares of the company’s stock worth $2,728,000 after buying an additional 408,170 shares during the last quarter. 62.47% of the stock is currently owned by institutional investors and hedge funds.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.